Das IOZK ist ein translationales Zentrum und entwickelt immunonkologische Verfahren auf der Basis neuer wissenschaftlicher Erkenntnisse.
Diese werden für die Patienten individuell in der bestmöglichen Weise kombiniert. Deshalb werden im IOZK keine randomisierten, klinischen Studien durchgeführt. Diese erfordern nämlich das gleiche Behandlungsprotokoll für alle Patienten in der Experimentalgruppe und eine Vergleichsgruppe, die keine Behandlung erhält. In der Wissenschaft werden neue Erkenntnismethoden entwickelt und diskutiert, die besser geeignet sind, die Wirksamkeit einer stark individualisierten Therapie zu untersuchen. Es ist uns ein großes Anliegen, zum wissenschaftlichen Fortschritt und der Entwicklung der modernen Immuntherapie gegen Tumorkrankheiten beizutragen.
Hier stellen wir wissenschaftliche Arbeiten zur Verfügung, die von Mitarbeitern des IOZK veröffentlicht wurden.
Dendritic cell therapy of high-grade gliomas
Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus
Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase
Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus
Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus
Vaccine therapy in patients with renal cell carcinoma
Randomized clinical studies of anti-tumor vaccination: state of the art in 2008
Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer
Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2
Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy
Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer
Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial
Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme
An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins
Second International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007
Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells
Dendritic cell vaccination in patients with malignant gliomas: current status and future directions
Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study
Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report